GlassScriptPhysician profile
Alberto Bessudo
NPI 1003888074
$54,590.71
in general payments reported to CMS, 2019-2025
100 companies · $3,924 in 2025
The $3,924 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,370 · 2020: $10K · 2021: $4,671 · 2022: $9,537 · 2023: $8,076 · 2024: $14K · 2025: $3,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $7,606 · Honoraria: $1,500 · Travel and Lodging: $917 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,457.55 |
| Consulting Fee | $7,606.00 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $916.63 |
| Education | $107.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $10,369.79 | 2019-2025 | |
| Daiichi Sankyo INC. | $6,389.08 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $4,325.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,343.02 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Karyopharm Therapeutics INC. | $2,408.92 | 2020-2024 | Xpovio |
| Epizyme, INC. | $2,374.35 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $1,698.13 | 2023 | Firdapse |
| Novartis Pharmaceuticals Corporation | $1,690.91 | 2019-2025 | |
| Morphosys, US INC. | $1,482.36 | 2022-2023 | Monjuvi |
| Merck Sharp & Dohme LLC | $1,441.17 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,248.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $989.04 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $974.67 | 2019-2025 | Imfinzi, Tagrisso |
| Ipsen Biopharmaceuticals, INC | $854.69 | 2019-2025 | Tazverik, Onivyde, Somatuline Depot |
| Amgen INC. | $830.72 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
Show all 98 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $743.58 | 2019-2024 | Erleada, Darzalex, Tecvayli |
| Alexion Pharmaceuticals, INC. | $730.45 | 2024-2025 | Ultomiris |
| Abbvie INC. | $647.59 | 2019-2025 | Venclexta, Lupron Depot |
| Pharmacyclics LLC, An Abbvie Company | $629.87 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $600.43 | 2019-2025 | Reblozyl, Opdivo, Breyanzi |
| Gilead Sciences, INC. | $596.75 | 2019-2025 | Trodelvy |
| Genmab U.S., INC. | $503.73 | 2023-2025 | Epkinly |
| Impedimed, INC. | $500.00 | 2022 | |
| Eisai INC. | $401.12 | 2019-2025 | |
| Genentech USA, INC. | $382.63 | 2019-2024 | Columvi, Lunsumio, Polivy |
| Foundation Medicine, INC. | $371.52 | 2019-2022 | |
| Array Biopharma INC | $369.35 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $353.71 | 2019-2025 | Cabometyx |
| Sobi, INC | $347.33 | 2022-2025 | |
| Incyte Corporation | $323.23 | 2019-2025 | Jakafi, Monjuvi |
| Pharmaessentia USA Corporation | $320.50 | 2023-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $318.39 | 2021-2025 | Libtayo, Lynozyfic |
| Blueprint Medicines Corporation | $308.65 | 2021-2024 | Ayvakit |
| Seagen INC. | $300.61 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $298.89 | 2019-2024 | Ninlaro, Alunbrig |
| Mirati Therapeutics, INC. | $273.66 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $271.51 | 2019-2025 | Xospata, Padcev, Vyloy |
| Cardinal Health 108 LLC | $253.56 | 2019 | |
| Aveo Pharmaceuticals, INC. | $225.70 | 2024-2025 | |
| Lilly USA, LLC | $223.88 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Servier Pharmaceuticals LLC | $220.07 | 2022-2024 | |
| Puma Biotechnology, INC. | $213.47 | 2019-2023 | Nerlynx |
| Emd Serono, INC. | $183.83 | 2019-2025 | Bavencio |
| Kite Pharma, INC. | $159.71 | 2021-2024 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.83 | 2019-2024 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $129.98 | 2019-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $124.36 | 2022-2024 | Brukinsa, Tevimbra |
| Si-Bone, INC. | $116.28 | 2025 | |
| Coherus Oncology, INC. | $115.47 | 2020-2025 | Loqtorzi |
| Immunogen, INC. | $114.69 | 2023 | Elahere |
| Taiho Oncology, INC. | $114.43 | 2021-2022 | |
| Eagle Pharmaceuticals, INC. | $114.28 | 2023 | |
| Adc Therapeutics America, INC. | $110.28 | 2021-2023 | |
| Tersera Therapeutics LLC | $107.70 | 2021-2024 | Zoladex, Xermelo |
| Deciphera Pharmaceuticals INC. | $106.86 | 2021-2024 | Qinlock |
| Verity Pharmaceuticals INC. | $106.21 | 2024 | Trelstar |
| Accord Healthcare, INC. | $105.93 | 2023-2025 | |
| Stemline Therapeutics INC. | $101.68 | 2023-2025 | Orserdu |
| Amag Pharmaceuticals, INC. | $98.86 | 2019 | |
| Beone Medicines USA, INC. | $82.59 | 2025 | Brukinsa, Tevimbra |
| Heron Therapeutics, INC. | $75.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $66.77 | 2019 | |
| Dendreon Pharmaceuticals LLC | $66.37 | 2024 | Provenge |
| Cumberland Pharmaceuticals, INC. | $57.93 | 2023-2025 | Sancuso |
| Edwards Lifesciences Corporation | $57.54 | 2024 | Sapien 3 Ultra Resilia |
| Agios Pharmaceuticals, INC. | $57.12 | 2024 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $56.54 | 2025 | |
| Mckesson Specialty Care Distribution, LLC | $54.85 | 2019 | |
| Octapharma USA, INC. | $54.40 | 2022-2024 | Octagam Immune Globulin (Human) |
| Acrotech Biopharma INC. | $53.80 | 2022 | |
| Myovant Sciences INC. | $53.34 | 2021-2022 | |
| Dova Pharmaceuticals | $45.95 | 2019-2021 | |
| Fennec Pharmaceuticals, INC. | $39.37 | 2024-2025 | Pedmark, Fyarro |
| Apellis Pharmaceuticals, INC. | $38.19 | 2022 | |
| Jazz Pharmaceuticals INC. | $37.03 | 2023-2025 | |
| Iovance Biotherapeutics, INC. | $35.98 | 2025 | Amtagvi |
| Secura Bio, INC. | $27.48 | 2019-2020 | |
| Springworks Therapeutics, INC. | $26.86 | 2025 | Ogsiveo |
| Eusa Pharma (US) LLC | $26.64 | 2021 | |
| Geron Corporation | $25.86 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $25.83 | 2019-2025 | |
| Tempus Ai, INC | $25.57 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $24.22 | 2019 | |
| Sumitomo Pharma America, INC. | $24.06 | 2025 | Orgovyx |
| Mylan Institutional INC. | $23.50 | 2019 | |
| Pharmacosmos Therapeutics INC. | $20.45 | 2024 | Cosela |
| Caris Mpi, INC. | $20.20 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $19.84 | 2019 | |
| Novocure INC. | $19.79 | 2025 | Optune Gio |
| Recordati_rare_diseases_inc. | $18.18 | 2025 | Enjaymo |
| Azurity Pharmaceuticals, INC. | $17.64 | 2025 | Danziten |
| Shire North American Group INC | $17.26 | 2019 | |
| Kyowa Kirin, INC. | $16.42 | 2019 | |
| Csl Behring | $15.20 | 2019 | |
| Menarini Silicon Biosystems, INC. | $14.29 | 2023 | Cellsearch |
| Genentech, INC. | $14.05 | 2023 | Actemra |
| Clovis Oncology, INC. | $13.96 | 2020 | |
| Aurobindo Pharma USA, INC. | $12.64 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$746.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Bessudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.